Health Care & Life Sciences » Biotechnology | Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
64.00
73.00
252.00
970.00
1,410.00
3,083
Gross Income
64.00
73.00
252.00
970.00
1,410.00
21,098
SG&A Expense
22,106.00
49,499.00
74,834.00
95,902.00
144,283.00
230,840
EBIT
22,170.00
49,572.00
75,086.00
96,872.00
145,693.00
209,742
Unusual Expense
6,454.00
400.00
-
-
-
-
Non Operating Income/Expense
1,271.00
2,467.00
3,355.00
543.00
555.00
23,722
Interest Expense
3,795.00
628.00
2,493.00
2,537.00
2,368.00
2,531
Pretax Income
31,148.00
48,133.00
74,224.00
98,866.00
146,863.00
232,566
Income Tax
-
-
139.00
193.00
1,758.00
3
Consolidated Net Income
31,148.00
48,133.00
74,363.00
99,059.00
145,105.00
232,569
Net Income
31,148.00
48,133.00
74,363.00
99,059.00
145,105.00
232,569
Net Income After Extraordinaries
31,148.00
48,133.00
74,363.00
99,059.00
145,105.00
232,569
Net Income Available to Common
31,598.00
48,133.00
74,363.00
99,059.00
145,105.00
232,569
EPS (Basic)
6.38
2.00
2.88
3.40
4.11
5.58
Basic Shares Outstanding
4,955.80
24,086.70
25,781.20
29,135.60
35,324.50
41,664
EPS (Diluted)
6.38
2.00
2.88
3.40
4.11
5.58
Diluted Shares Outstanding
4,955.80
24,086.70
25,781.20
29,135.60
35,324.50
41,664
EBITDA
22,106.00
49,499.00
74,834.00
95,902.00
144,283.00
207,300
Non-Operating Interest Income
-
-
-
-
1,753.00
3,429
Preferred Dividends
450.00
-
-
-
-
-

About Aerie Pharmaceuticals

View Profile
Address
4301 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.aeriepharma.com
Updated 07/08/2019
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.